This study is for people with multiple myeloma, a type of blood cancer. It tests the best dose of a drug called melphalan, which is used with a stem cell transplant, a process where damaged cells are replaced with healthy ones. Melphalan helps stop cancer cells from growing in different ways. In this study, doctors will measure how much melphalan is in each person’s blood to decide the best dose for them. This is called pharmacokinetic analysis.
Key Points:
- The study involves several visits over a few months with check-ups on days 7, 14, 30, 60, and 90.
- Participants receive melphalan on two days and then get a stem cell transplant.
- Risks include typical side effects from chemotherapy, and participants must meet specific health criteria to join.
The study is looking for the safest way to use melphalan by adjusting doses for each person, which may lead to better treatment outcomes. Participants need to meet certain health conditions and agree to use birth control to join the study. People with certain heart problems or infections like HIV or hepatitis may not be eligible.